 |
Video: What is a Stock Split?
|
 |
| Dermata Therapeutics, Inc. is a late-stage medical dermatology company. Co. is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a U.S. market size of approximately 50 million patients. According to our DRMA split history records, Dermata Therapeutics has had 3 splits. | |
 |

Dermata Therapeutics (DRMA) has 3 splits in our DRMA split history database. The first split for DRMA took place on March 14, 2023. This was a 1 for 16 reverse split, meaning for each 16 shares of DRMA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 62.5 share position following the split. DRMA's second split took place on May 16, 2024. This was a 1 for 15 reverse split, meaning for each 15 shares of DRMA owned pre-split, the shareholder now owned 1 share. For example, a 62.5 share position pre-split, became a 4.16666666666667 share position following the split. DRMA's third split took place on August 01, 2025. This was a 1 for 10 reverse split, meaning for each 10 shares of DRMA owned pre-split, the shareholder now owned 1 share. For example, a 4.16666666666667 share position pre-split, became a 0.416666666666667 share position following the split.
When a company such as Dermata Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the DRMA split history from start to finish, an original position size of 1000 shares would have turned into 0.416666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Dermata Therapeutics shares, starting with a $10,000 purchase of DRMA, presented on a split-history-adjusted basis factoring in the complete DRMA split history.

Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
08/16/2021 |
|
| End date: |
11/18/2025 |
|
| Start price/share: |
$12,672.00 |
|
| End price/share: |
$2.67 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.98% |
|
| Average Annual Total Return: |
-86.29% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$2.11 |
|
| Years: |
4.26 |
|
|
 |
| Date |
Ratio |
| 03/14/2023 | 1 for 16 | | 05/16/2024 | 1 for 15 | | 08/01/2025 | 1 for 10 |
|
 |